Multiple Sclerosis Research Today is a free monthly online journal that collates and summarizes the latest research about Multiple Sclerosis, including details on diagnosis, symptoms, treatment, prognosis.

Volume 3 (2006), Issue 8 (August)

1. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment.
   Eur J Neurol, 13(8): 887-95. [Abstract] [Full-text]
2. Avascular necrosis of the bones: an overlooked complication of pulse steroid treatment of multiple sclerosis.
   Eur J Neurol, 13(8): 857-61. [Abstract] [Full-text]
3. Evidence of early childhood as the susceptibility period in multiple sclerosis: space-time cluster analysis in a Sardinian population.
   Am J Epidemiol, 164(4): 326-33. [Abstract] [Full-text]
4. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis.
   Neurology, 67(3): 511-3. [Abstract] [Full-text]
5. Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study.
   Arch Neurol, 63(8): 1175-80. [Abstract] [Full-text]
6. Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis.
   J Neurol Neurosurg Psychiatry, 77(9): 1036-9. [Abstract] [Full-text]
7. Is the frequency of abnormalities on magnetic resonance imaging in isolated optic neuritis related to the prevalence of multiple sclerosis? A global comparison.
   J Neurol Neurosurg Psychiatry, 77(9): 1070-2. [Abstract] [Full-text]
8. Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study.
   J Neurol Neurosurg Psychiatry, 77(9): 1030-5. [Abstract] [Full-text]
9. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG.
   J Neurol Neurosurg Psychiatry, 77(9): 1073-5. [Abstract] [Full-text]
10. Conformation-activity relationship of designed glycopeptides as synthetic probes for the detection of autoantibodies, biomarkers of multiple sclerosis.
    J Med Chem, 49(17): 5072-9. [Abstract] [Full-text]
11. An investigation of polymorphisms in the 17q11.2-12 CC chemokine gene cluster for association with multiple sclerosis in Australians.
    BMC Med Genet, 7: 64. [Abstract] [Full-text]
12. The risk of relapses in multiple sclerosis during systemic infections.
    Neurology, 67(4): 652-9. [Abstract] [Full-text]
13. Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter.
    Radiology, 240(3): 811-20. [Abstract] [Full-text]
14. Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis.
    Eur J Neurol, 13(9): 1014-21. [Abstract] [Full-text]
15. Utility of the National Eye Institute VFQ-25 questionnaire in a heterogeneous group of multiple sclerosis patients.
    Am J Ophthalmol, 142(3): 464-8. [Abstract] [Full-text]
16. Risk factors for falling among people aged 45 to 90 years with multiple sclerosis.
    Arch Phys Med Rehabil, 87(9): 1274-9; quiz 1287. [Abstract] [Full-text]

© 2004-2012 Multiple Sclerosis Research Today. All Rights Reserved.